Previous 10 | Next 10 |
Geneva, Switzerland and Boston, MA – February 18, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that CEO Ernest Loumaye will presen...
Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that CEO Ernest Loumaye will present an ...
ObsEva (NASDAQ: OBSV ) initiated with Buy rating and $19 (395% upside) price target at Kempen & Co. Shares up 8% premarket. More news on: ObsEva SA, Selecta Biosciences, Inc., BioPharmX Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
ObsEva SA (NASDAQ: OBSV ) will provide corporate plans for 2020 and beyond during 2020 JP Morgan Conference in San Francisco. More news on: ObsEva SA, Healthcare stocks news, Read more ...
Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020 Enrollment of linzagolix US and EU Phase 3 trials in endometriosis on track Phase 2 results of OBE022 expected in 2H:20 Corp...
Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...
ObsEva (NASDAQ: OBSV ) and Yuyuan BioScience Technology have entered into a sublicense agreement to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women undergoing embryo transfer following in-vitro fertilization in the People's Republic of Chi...
Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a sublicense agreement to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women ...
Geneva, Switzerland and Boston, MA – January 7, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will be participating i...
Gainers: Intra-Cellular Therapies (NASDAQ: ITCI ) +204% . More news on: Intra-Cellular Therapies, Inc., Cassava Sciences, Inc., Microbot Medical Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...